Gianluca Baldini

Dr. Gianluca Baldini


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Serena AltamuraSerena Altamura
Serena Altamura
GOGino Orsini
Gino Orsini
GBGianluca Baldini
Gianluca Baldini
Maria Grazia CifoneMaria Grazia Cifone
Maria Grazia Cifone
MGMaurizio Giuliani
Maurizio Giuliani
Background/Objectives: Breast implants are widely used in aesthetic and reconstructive surgery. Although they are not associated with an increased risk of breast carcinoma, growing attention has focused on implant-associated conditions, including breast implant-associated malignancies, breast implant illness (BII), and autoimmune or inflammatory manifestations. This review examines current evidence and explores the potential role of chronic inflammation and the host–implant–microbiome interface in these conditions. Methods: A narrative review was conducted focusing on implant-associated malignancies, BII, autoimmune manifestations, chronic inflammation, implant-associated biofilms, and host–implant interactions. Evidence from oncology, immunology, microbiology, and biomaterials research was integrated to evaluate potential mechanisms underlying implant-associated local and systemic manifestations. Results: Recent evidence suggests that prolonged host–implant interactions, persistent foreign body responses, implant-associated biofilms, microbial persistence, and chronic immune stimulation may contribute to long-term alterations within the peri-implant environment. These mechanisms have been proposed as potential contributors to breast implant-associated malignancies, as well as to systemic manifestations such as BII and autoimmune or inflammatory conditions. Although BII and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) have received increasing attention, causal relationships with breast implants remain unproven, and available evidence is limited by methodological heterogeneity, lack of standardized diagnostic criteria, and potential confounding factors. Conclusions: Emerging evidence highlights a complex interplay among implanted biomaterials, microbial biofilms, and host immune responses. The host–implant–microbiome interface may promote a biological environment that promotes persistent immune stimulation and chronic low-grade inflammation, providing a biologically plausible framework for interpreting heterogeneous implant-associated conditions. Further studies are needed to clarify the role of host–implant–microbiome interactions in implant-associated local and systemic manifestations.

Verified
Journal Article
Open access
PDF file
YAYlli Alicka
Ylli Alicka
STSkender Topi
Skender Topi
EGElona Gaxhja
Elona Gaxhja
GBGianluca Baldini
Gianluca Baldini
GOGino Orsini
Gino Orsini
Serena AltamuraSerena Altamura
Serena Altamura
Lip squamous cell carcinoma (LSCC) is a distinct subtype of head and neck squamous cell carcinoma strongly associated with ultraviolet (UV) radiation exposure and characterized by unique molecular, immune, and microenvironmental features. Although UV-induced photodamage represents the principal initiating event, increasing evidence indicates that LSCC progression results from complex interactions among genetic and epigenetic alterations, dysregulated signaling pathways, chronic inflammation, immune dysregulation, host–microbiome dynamics, and tumor microenvironment (TME) remodeling. Recent advances have expanded the traditional view of LSCC by highlighting the contributions of UV-induced DNA damage, tumor protein p53 (TP53) alterations, epigenetic reprogramming, aberrant activation of key signaling pathways, and progressive immune escape mechanisms. In parallel, growing attention has focused on the role of cancer-associated fibroblasts (CAFs), stromal remodeling, microbial dysbiosis, and disruption of the microbiome–immune–metabolic axis as important modulators of disease progression and biological heterogeneity. Emerging biomarkers, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), epigenetic signatures, liquid-biopsy analytes, immune-related markers, and microbiome-associated profiles, together with artificial intelligence (AI)-based analytical approaches, are creating new opportunities for diagnosis, risk stratification, disease monitoring, and precision oncology. Rather than providing a conventional descriptive overview, this review proposes an integrated conceptual framework in which molecular, immune, microbial, and microenvironmental drivers interact through continuous bidirectional crosstalk to shape LSCC initiation, progression, therapeutic responsiveness, and clinical heterogeneity. This system-oriented perspective may provide a foundation for future biomarker-guided and biologically informed approaches to LSCC management.